Daily injection of KBP/placebo for up to 28 days
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type II Diabetes Mellitus
Conditions
Type II Diabetes Mellitus
Trial Timeline
Apr 17, 2018 → Dec 3, 2019
NCT ID
NCT03907202About Daily injection of KBP/placebo for up to 28 days
Daily injection of KBP/placebo for up to 28 days is a phase 1 stage product being developed by Eli Lilly for Type II Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT03907202. Target conditions include Type II Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type II Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03907202 | Phase 1 | Terminated |
Competing Products
20 competing products in Type II Diabetes Mellitus